
RadNet eyes $200M debt raise for imaging expansion
The proposed incremental term loan would support acquisitions, organic expansion, health system partnerships, and general corporate purposes.
Section
M&A, vendor news, reimbursement, and the economics of imaging.

The proposed incremental term loan would support acquisitions, organic expansion, health system partnerships, and general corporate purposes.

The agreement gives Tolmar exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer and includes upfront funding, manufacturing support, and milestone payments.

RadX operates 26 independent outpatient radiology centers across Florida, Michigan, Maryland, Georgia, Tennessee, and Alabama.

Telix and United Imaging Healthcare North America will evaluate a U.S. research collaboration focused on scanner, software, AI, and radiopharmaceutical workflow integration.

The Series C-backed growth capital brings Subtle Medical’s total funding to $86M as the company scales its vendor-neutral AI imaging platform across MRI, PET, and CT.

Perceptive Discovery and Certis Oncology will combine patient-derived xenograft tumor models with radiochemistry, imaging, pharmacology, and quantitative analysis capabilities.

The partnership expands Lumexa Imaging’s New York presence and is expected to support future outpatient imaging locations across the city’s metro area.

The binding agreement would add a Vienna-based team, a CE-marked chest CT product suite, German reimbursement contracts, and a route for CT expansion in Europe.

Align Capital Partners acquired the Boise-based mobile imaging provider, which serves hospitals and healthcare facilities across 14 states.

United Imaging used SNMMI 2026 to show new PET/CT and PET/MR systems, including uMI Panvivo Mobile, uMI Panorama GS, and uPMR Zenith.

PharmaLogic will expand production capacity for Ratio Therapeutics’ Ac-225 RTX-2358 as the FAP-targeted radiopharmaceutical moves through ATLAS clinical testing.

The EMA-authorized radiopharmaceutical precursor is produced at SHINE’s Cassiopeia facility in Wisconsin for use in radiolabelling carrier medicines.

The joint venture is intended to combine radiopharmaceutical production, molecular imaging, molecular therapy, and clinical trials in a vertically integrated model.

hor Medical will initially supply Pb-212 to Eckert & Ziegler for preclinical R&D, while the companies explore broader isotope-production and radiopharmaceutical-manufacturing integration.

Christopher Young will lead global expansion, partnerships, and enterprise growth after prior healthcare technology roles at BCG and Ascension.